Translation

PATENT COOPERATION TRE

RECEIVED

OCT 0 7 2002

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT CENTER 1600/2900

(PCT Article 36 and Rule 70)

	(1 O 1 / Helolo 30 and Raio 70)	10/019902	
Applicant's or agent's file reference EA-PCT-11177 FOR FURTHER ACTION See Notification of Transmittal of Internation Preliminary Examination Report (Form PCT/IPEA/410)			
International application No.	International filing date (day/month/year)	Priority date (day/month/year)	
PCT/EP00/06139	30 June 2000 (30.06.00)	30 June 1999 (30.06.99)	
International Patent Classification (IPC) or national classification and IPC A61K 47/48			
Applicant SYNTESOME GESELLSCHAFT FÜR MEDIZINISCHE BIOCHEMIE MBH			
 This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 			
2. This REPORT consists of a total of	sheets, including this cover s	heet.	
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).			
These annexes consist of a t	total of sheets.		
3. This report contains indications rela	3. This report contains indications relating to the following items:		
I Basis of the report			
II Priority			
III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability		step and industrial applicability	
IV Lack of unity of invention			
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
VI Certain documents cited			
VII Certain defects in the international application			
VIII Certain observations on the international application			
Date of submission of the demand Date of completion of this report			
05 January 2001 (05.0	30	30 May 2002 (30.05.2002)	
Name and mailing address of the IPEA/EP	Authorized officer	Authorized officer	

Telephone No.

Facsimile No.

ernational application No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT/EP00/06139

1. Basis of the report				
1. This repo under Arti	ort has been drawn of cle 14 are referred to	on the basis of (Replacement she in this report as "originally filea	tets which have been furnished to the receiving Office in response to an invitation " and are not annexed to the report since they do not contain amendments.):	
	the international	application as originally filed	l.	
	the description,	pages1-49	, as originally filed,	
		pages	, filed with the demand,	
		pages	, filed with the letter of,	
		pages	, filed with the letter of ·	
	the claims,	Nos. 1-24	, as originally filed,	
		Nos.	, as amended under Article 19,	
		Nos.	, filed with the demand,	
		Nos.	, filed with the letter of,	
* 1		Nos.	, filed with the letter of	
	the drawings,	sheets/fig1/3-3/3	, as originally filed,	
		sheets/fig	, filed with the demand,	
j.		sheets/fig	, filed with the letter of,	
		sheets/fig	, filed with the letter of	
2. The amen	dments have result	ed in the cancellation of:		
	the description,	pages	_	
	the claims,	Nos.	_	
	the drawings,	sheets/fig		
3. Th	is report has been e go beyond the discl	stablished as if (some of) the a osure as filed, as indicated in	amendments had not been made, since they have been considered the Supplemental Box (Rule 70.2(c)).	
4. Additions	al observations, if n	ecessary:		
	, ·	,·		
		•		
			•	
1				

mernational application No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT/EP00/06139

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
The que industri	estions whether the claimed invention appears to be novel, to involve an inventive step (to be ally applicable have not been examined in respect of:	non obvious), or to be	
	the entire international application.		
\boxtimes	claims Nos		
because	:		
	the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary ex	amination (specify):	
	the description, claims or drawings (indicate particular elements below) or said claims Nos are so unclear that no meaningful opinion could be formed (specify):		
	ac so unclear that no meaningful opinion could be formed (spectyy).		
	the claims, or said claims Nos.	_ are so inadequately supported	
╽╙	by the description that no meaningful opinion could be formed.		
\boxtimes	no international search report has been established for said claims Nos.	1-24	

Sun	plemental Bo	18

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: III

Due to a lack of clarity, the search was limited to sialated conjugates, as follows from the examples. The substantive examination was consequently restricted.

ernational application No.
PCT/EP 00/06139

V.	Reasoned statement under Article 3 citations and explanations supporting		inventive step or industrial app	licability;
1.	Statement			
	Novelty (N)	Claims	1-24	YES
		Claims		NO
	Inventive step (IS)	Claims		YES
		Claims	1-24	NO
	Industrial applicability (IA)	Claims	1-24	YES
		Claims		NO

2. Citations and explanations

Reference is made to the following documents:

- D1: REUTER J D et al.: "Inhibition of Viral Adhesion and Infection by Sialic-acid-Conjugated Dendritic Polymers"

 BIOCONJUGATE CHEMISTRY, Vol. 10, No. 2, March 1999
 (1999-03), pages 271-278, XP000804253 ISSN: 1043-1802
- D2: ZANINI D et al.: "NOVEL DENDRITIC ALPHA-SIALOSIDES: SYNTHESIS OF GLYCODENDRIMERS BASED ON A 3,3'IMINOBIS(PROPYLAMINE) CORE"

 JOURNAL OF ORGANIC CHEMISTRY, Vol. 61, No. 21, 18
 October 1996 (1996-10-18), pages 7348-7354,

 XP002042912 ISSN: 0022-3263
- D3: WU W-Y et al.: "Synthesis of a polymeric 4-N-linked sialoside which inhibits influenza virus hemagglutinin"

 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol. 10, No. 4, February 2000 (2000-02), pages 341-343, XP004189928 ISSN: 0960-894X
- D4: Gambaryan A S et al.: "Specification of Receptorbinding Phenotypes of Influenza Virus Isolates from Different Hosts Using Synthetic Sialylglycopolymers: Non-EGG-adapted Human H1 and H3 Influenza A and

Influenza B Viruses Share a Common High Binding
Affinity for 6'-sialyl-(N-acetyllactosamine)"
VIROLOGY, Vol. 232, No. 2, 9 June 1997 (1997-06-09),
pages 345-350, XP002068479 ISSN: 0042-6822

D5: Reuter J et al.: "Sialic acid conjugated dendritic polymers inhibit influenza virus binding to target cells in a structural and virus strain-specific manner"

Abstracts of the General Meeting of the American Society for Microbiology, Vol. 98, 1998, page 51 &: 98th General Meeting of the American Society for Microbiology; Atlanta, Georgia, USA; May 17-21, 1998, 1998 ISSN: 1060-2011

D6: YAMADA K et al.: "High performance polymer supports for enzyme-assisted synthesis of glycoconjugates"

CARBOHYDRATE RESEARCH, Vol. 305, No. 3-4, 1 December 1997 (1997-12-01), pages 443-461, XP004131532 ISSN: 0008-6215.

The present application claims conjugates of sialic acid with a dendrimer. If the chains of the dendrimer are longer, aggregates are formed which improve the presentation of the sialic acid groups. This basis of the invention is supported in the present application by a single comparative example (see Table 9, page 48).

The use of sialated polymers to inhibit viral cell adhesion is already known from, inter alia, **D1** to **D5**. The invention on which the application is based differs from this prior art in that the chain length is increased.

Insofar as it relates to 6'SLN, the applicant has shown clearly that the claimed conjugates have a significantly improved effect. This improved effect could be used as an argument in support of an inventive step.

However, the comparative example for the compound No. 48 shows a lower activity compared to a comparable conjugate. Consequently, it is clear that the chain length is not responsible in all cases for the formation of aggregates and thus for the improved activity, but rather that the sugar group too has a certain influence on the effect of the conjugate produced. Accordingly, it is not possible to ascertain whether the difference as per the invention is in fact responsible for the improved effect.

Since the International Preliminary Examining Authority is unable to ascertain whether the difference between the prior art and the invention does in fact lead to the claimed improvement, it is not possible at present to acknowledge an inventive step for all of the claimed conjugates.

Supplemental Box


(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: VI

Certain published documents (PCT Rule 70.10)

Patent No. Publication date Filing date Priority date

WO 00 55149 21.9.2000 9.3.2000 12.3.1999



VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The current claims relate to a conjugate, a method for the production of same, or the use of same, wherein the characteristic group R of this conjugate is defined merely by desired properties. The use of these parameters in the given context appears to give rise to a lack of clarity (PCT Article 6). It is not possible to compare the parameters chosen by the applicant with the disclosure of the prior art in this regard.